AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8273801 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes during the late phase of GB emptying (S20-40)
Number of subjects: 10
Study 8273801 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes during the early phase of GB emptying (S0-20)
Number of subjects: 10
Study 8273801 — intervention group
Group type: COMPARATOR
Intervention: Control test without smoking (C)
Number of subjects: 10
Study 2644344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 63
Study 2644344 — intervention group
Group type: COMPARATOR
Intervention: Amineptine
Number of subjects: 63
Study 790412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 790412 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 0
Study 31274007 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (1-3 individual and 6 group sessions)
Number of subjects: 80
Study 31274007 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 80
Study 31274007 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 80
Study 30031368 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded in vivo exposure (EXP)
Number of subjects: 12
Study 30031368 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 12
Study 27603948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrax (mechanical vibrations) applied for 5 minutes
Number of subjects: 23
Study 27603948 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received cardiovascular training with mobilization and active breathing exercises
Number of subjects: 23
Study 23832167 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular function training (SFT)
Number of subjects: 47
Study 23832167 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 22561380 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized task-oriented ambulation training (30-45 mins, three times a week for 4 weeks)
Number of subjects: 50
Study 22561380 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 50
Study 20569068 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose BoNTA (200-240 U)
Number of subjects: 109
Study 20569068 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose BoNTA (120-150 U)
Number of subjects: 109
Study 20569068 — intervention group
Group type: COMPARATOR
Intervention: BoNTA (both doses)
Number of subjects: 109
Study 18502002 — intervention group
Group type: EXPERIMENTAL
Intervention: NYVAC-C (20 participants)
Number of subjects: 24
Study 18502002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 participants)
Number of subjects: 24
Study 15992393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (10,000 lux, 1 h daily)
Number of subjects: 102
Study 15992393 — intervention group
Group type: COMPARATOR
Intervention: Dim light therapy (50 lux, 30 min daily)
Number of subjects: 102
Study 12849763 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal cerebellar lesions
Number of subjects: 16
Study 12849763 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (matched for age, gender, and years of education)
Number of subjects: 16
Study 10499749 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL 6% hetastarch (group H)
Number of subjects: 24
Study 10499749 — intervention group
Group type: COMPARATOR
Intervention: 1500 mL lactated Ringer's solution (group R)
Number of subjects: 24
Study 9030391 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC and zidovudine combination
Number of subjects: 0
Study 9030391 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study 1800872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg intrathecal morphine
Number of subjects: 63
Study 1800872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg intrathecal morphine
Number of subjects: 63
Study 1800872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg intrathecal morphine
Number of subjects: 63
Study 1800872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 63
Study 1800872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg intrathecal morphine
Number of subjects: 63
Study 1800872 — intervention group
Group type: COMPARATOR
Intervention: 0 mg intrathecal morphine (control)
Number of subjects: 63
Study 1800872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg to 0.125 mg intrathecal morphine
Number of subjects: 63
Study 1800872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg to 0.125 mg intrathecal morphine
Number of subjects: 63
Study 6323335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg nightly)
Number of subjects: 110
Study 6323335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg nightly)
Number of subjects: 110
Study 6323335 — intervention group
Group type: COMPARATOR
Intervention: Antacids as needed for symptomatic relief
Number of subjects: 110
Study 30859976 — intervention group
Group type: EXPERIMENTAL
Intervention: PGx-guided care arm
Number of subjects: 1167
Study 30859976 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) arm
Number of subjects: 1167
Study 30859976 — intervention group
Group type: EXPERIMENTAL
Intervention: PGx-guided care arm (incongruent to congruent medication change)
Number of subjects: 1167
Study 29493798 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 0
Study 27021502 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-grasping method
Number of subjects: 28
Study 27021502 — intervention group
Group type: COMPARATOR
Intervention: Direct method
Number of subjects: 28
Study 24601857 — intervention group
Group type: EXPERIMENTAL
Intervention: SALT
Number of subjects: 43
Study 24601857 — intervention group
Group type: COMPARATOR
Intervention: JumpSTART
Number of subjects: 43
Study 24601857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 43
Study 22878451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg
Number of subjects: 9
Study 22878451 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 9
Study 20805299 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 175 mg once daily
Number of subjects: 81
Study 20805299 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 50 mg once daily
Number of subjects: 81
Study 20805299 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 125 mg once daily
Number of subjects: 81
Study 20805299 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 81
Study 17295731 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief skills training program (BSTP)
Number of subjects: 556
Study 17295731 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-step-influenced (TSI) program
Number of subjects: 556
Study 17295731 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 556
Study 15699376 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of IV metoclopramide, given up to four times over 2 hours
Number of subjects: 78
Study 15699376 — intervention group
Group type: COMPARATOR
Intervention: 6 mg of subcutaneous sumatriptan
Number of subjects: 78
Study 11875637 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g branch chain amino acids
Number of subjects: 12
Study 11875637 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g branch chain amino acids
Number of subjects: 12
Study 11875637 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g branch chain amino acids
Number of subjects: 12
Study 10195774 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 930
Study 10195774 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-PRP-T
Number of subjects: 930
Study 10195774 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-PRP-T
Number of subjects: 930
Study 10195774 — intervention group
Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 930
Study 10195774 — intervention group
Group type: COMPARATOR
Intervention: Acellular pertussis vaccine
Number of subjects: 930
Study 7781259 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (10 mg orally and intravenously)
Number of subjects: 16
Study 7781259 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg orally and 20 mg intravenously)
Number of subjects: 16
Study 7781259 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 16
Study 7781259 — intervention group
Group type: COMPARATOR
Intervention: All four treatments (torsemide and furosemide in both oral and intravenous forms)
Number of subjects: 16
Study 7781259 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide and Furosemide
Number of subjects: 16
Study 2184187 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary geriatric assessment
Number of subjects: 142
Study 2184187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no geriatric assessment)
Number of subjects: 142
Study 653509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (0.16 microgram/kg/h)
Number of subjects: 0
Study 653509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (0.32 microgram/kg/h)
Number of subjects: 0
Study 653509 — intervention group
Group type: COMPARATOR
Intervention: 0.15M NaCl (Control)
Number of subjects: 0
Study 30950637 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually titrated stimulant medication (MSM) for 8 weeks
Number of subjects: 35
Study 30950637 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent training (BPT) for 8 weeks
Number of subjects: 35
Study 30950637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment after initial treatment (MSM or BPT)
Number of subjects: 35
Study 30950637 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy treatment visits (MSM-MSM, BPT-BPT)
Number of subjects: 35
Study 29037483 — intervention group
Group type: EXPERIMENTAL
Intervention: 2014 guidelines for labor management
Number of subjects: 7845
Study 29037483 — intervention group
Group type: COMPARATOR
Intervention: 2010 guidelines for labor management
Number of subjects: 7845
Study 25449654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 0
Study 25449654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib with ketoconazole
Number of subjects: 0
Study 25449654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib with gemfibrozil
Number of subjects: 0
Study 23842127 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir
Number of subjects: 689
Study 23842127 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 689
Study 23842127 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained HIV-1 RNA suppression below 400 copies/ml
Number of subjects: 689
Study 23842127 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 testing
Number of subjects: 689
Study 23842127 — intervention group
Group type: EXPERIMENTAL
Intervention: continued testing for CD4 cell count after 48 weeks
Number of subjects: 689
Study 21968873 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip work estimation (GW)
Number of subjects: 291
Study 21968873 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength (GS), Fatigue resistance (FR), Grip work (GW), GW corrected for body weight (GW/BW)
Number of subjects: 291
Study 21968873 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating IL-6
Number of subjects: 291
Study 21968873 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha
Number of subjects: 291
Study 20031714 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 2271
Study 20031714 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 2271
Study 16461819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily for 8 weeks
Number of subjects: 80
Study 16461819 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 80
Study 15306578 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC treatment (omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 587
Study 15306578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587
Study 11159890 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 microg/kg IL-10
Number of subjects: 144
Study 11159890 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/kg IL-10
Number of subjects: 144
Study 11159890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 0)
Number of subjects: 144
Study 9692659 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 12
Study 9692659 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 12
Study 7889644 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ hybridization on fetal nucleated cells in maternal whole venous blood
Number of subjects: 39
Study 2883683 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine high dosage (270 mg +/- 37 mg/die)
Number of subjects: 20
Study 2883683 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine low dosage (168 mg +/- 15 mg/die)
Number of subjects: 20
Study 31046033 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of standardized Withania somnifera extract (WSE)
Number of subjects: 66
Study 31046033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 29641221 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 52
Study 29641221 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-tidal volume ventilation (LoTV)
Number of subjects: 52
Study 27572953 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 9013
Study 27572953 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 9013
Study 25353657 — intervention group
Group type: EXPERIMENTAL
Intervention: .12% chlorhexidine spray
Number of subjects: 26
Study 25353657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26
Study 22760564 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/d)
Number of subjects: 120
Study 22760564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19953428 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral deep brain stimulation (DBS) surgery
Number of subjects: 24
Study 19953428 — intervention group
Group type: COMPARATOR
Intervention: Control group (PD controls)
Number of subjects: 24
Study 17884515 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotic therapy
Number of subjects: 2932
Study 15336816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 329
Study 15336816 — intervention group
Group type: COMPARATOR
Intervention: Dietary control
Number of subjects: 329
Study 10901565 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal umbilical artery Doppler studies (n = 109)
Number of subjects: 186
Study 10901565 — intervention group
Group type: COMPARATOR
Intervention: Abnormal umbilical artery Doppler studies (n = 77)
Number of subjects: 186
Study 9333146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir (0.3% or 1%) gel applied once daily for 5 days
Number of subjects: 30
Study 9333146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir (0.3% or 1%) gel
Number of subjects: 30
Study 9333146 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 8469191 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (250 mg weekly)
Number of subjects: 413
Study 8469191 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 413
Study 8469191 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily) and primaquine (7.5 mg daily)
Number of subjects: 413
Study 8469191 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (50 mg daily) and chloroquine (300 mg weekly)
Number of subjects: 413
Study 3026264 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 69
Study 3026264 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 69
Study 3026264 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus Hydrochlorothiazide
Number of subjects: 69
Study 3026264 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 69
Study 2438962 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 14
Study 2438962 — intervention group
Group type: COMPARATOR
Intervention: Methysergide
Number of subjects: 14
Study 2438962 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 14
Study 2438962 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 14
Study 2438962 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin challenge
Number of subjects: 14
Study 31567929 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation with sphincter-preserving surgery
Number of subjects: 125
Study 31567929 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative increments of width of presacral space
Number of subjects: 125
Study 31567929 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative increments of thickness of rectal wall
Number of subjects: 125
Study 31567929 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative increments of distal end of sigmoid colon
Number of subjects: 125
Study 28166296 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC Soli 6 mg + TOCAS
Number of subjects: 1208
Study 28166296 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC Soli 9 mg + TOCAS
Number of subjects: 1208
Study 28166296 — intervention group
Group type: COMPARATOR
Intervention: TOCAS alone
Number of subjects: 1208
Study 28166296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1208
Study 28166296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall FDC Soli + TOCAS
Number of subjects: 1208
Study 25183340 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 28
Study 25183340 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mmol/kg gadopentetate dimeglumine
Number of subjects: 28
Study 23307659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataxic patients performing U-turns
Number of subjects: 9
Study 23307659 — intervention group
Group type: COMPARATOR
Intervention: Controls performing U-turns
Number of subjects: 9
Study 20464461 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle devices (steel, silicon, and polymer) applied to skin
Number of subjects: 2
Study 18274887 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 300 mg Ginkgo biloba extract (GBE)
Number of subjects: 99
Study 18274887 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term GBE (300 mg/daily) combined with sex therapy
Number of subjects: 99
Study 18274887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex therapy alone
Number of subjects: 99
Study 18274887 — intervention group
Group type: COMPARATOR
Intervention: Long-term GBE administration alone
Number of subjects: 99
Study 18274887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 16627376 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose, 100 mg three times a day
Number of subjects: 1368
Study 16627376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1368
Study 16627376 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 1368
Study 15531004 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 30 mg
Number of subjects: 160
Study 15531004 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 160
Study 15531004 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril + Manidipine
Number of subjects: 160
Study 15531004 — intervention group
Group type: COMPARATOR
Intervention: Enalapril + HCTZ
Number of subjects: 160
Study 11060816 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics or antiviral agents (specific regimens not detailed)
Number of subjects: 0
Study 11060816 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9262270 — intervention group
Group type: EXPERIMENTAL
Intervention: Humegon
Number of subjects: 181
Study 9262270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergonal
Number of subjects: 181
Study 8328663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray
Number of subjects: 47
Study 8328663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2868172 — intervention group
Group type: EXPERIMENTAL
Intervention: New measurement technique
Number of subjects: 0
Study 2868172 — intervention group
Group type: COMPARATOR
Intervention: Established measurement technique
Number of subjects: 0
Study 29641467 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium adherence to the Mediterranean diet
Number of subjects: 539
Study 29641467 — intervention group
Group type: EXPERIMENTAL
Intervention: Third quartile of the 'Western pattern' dietary pattern
Number of subjects: 539
Study 29641467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile of the 'Western pattern' dietary pattern
Number of subjects: 539
Study 29641467 — intervention group
Group type: EXPERIMENTAL
Intervention: Third quartile of the 'prudent pattern' dietary pattern
Number of subjects: 539
Study 26714115 — intervention group
Group type: EXPERIMENTAL
Intervention: MedXL 0.9% sodium chloride flush
Number of subjects: 75
Study 26714115 — intervention group
Group type: EXPERIMENTAL
Intervention: Becton-Dickinson 0.9% sodium chloride flush
Number of subjects: 75
Study 26714115 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride flush through central venous access devices
Number of subjects: 75
Study 26714115 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers tasting 0.9% sodium chloride from prefilled syringes
Number of subjects: 75
Study 25638303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice daily (BID)
Number of subjects: 112